Compare Fox Corp Class A (FOXA) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs GSK plc — how do they compare? Fox Corp Class A trades at $56.65 (market cap $22.28B), while GSK plc trades at $52.79 (market cap $101.34B). The key difference: GSK plc is far larger — about 4.5× Fox Corp Class A's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| FOXA | GSK | |
|---|---|---|
Market Cap | $22.28B | $101.34B |
Sector | Media | Health |
52-Week High | $76.11 | $61.18 |
52-Week Low | $48.79 | $36.20 |
Enterprise Value | $26.25B | $121.95B |
Dividend Yield | 1% | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fox Corporation (FOXA) trades at $55.94, up 1.95% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 14.73 and net income margin of 10.56%, supported by $3.32B in operating cash flow for 2025. Recent news highlights the strategic $22B Roku acquisition, positioning Fox in the competitive streaming landscape.
The outlook is mixed: analyst consensus targets $67.80 (21% upside) with equal buy/hold ratings, but technicals and 2026 cash flow projections signal caution. Key risks include integration challenges from the Roku deal and advertising market volatility. The stock presents a value opportunity if execution risks are managed.
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
